PURA BREAKING NEWS - Funding Completed
July 13 2020 - 3:13PM
InvestorsHub NewsWire
Dallas, TX --
July 13, 2020 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) Breaking News Update – The management buyout of a
separate public company that will in turn purchase PURA’s cannabis
cultivation spinoff in exchange for common stock has been
funded. The management/owner team plans to make a formal
announcement tomorrow, on Tuesday, July 14, 2020, to reveal details
regarding a planned dividend distribution of stock to PURA
shareholders.
The common stock
issued in exchange for the PURA spinoff is intended to be issued to
PURA shareholders in a dividend
distribution.
NCM Biotech, a
subsidiary of Kali-Extracts (USOTC:
KALY) will also be acquired and merged with PURA’s cannabis
spinoff.
The management
team purchasing control of the target public company is expected to
confirm the planned acquisitions of PURA’s cannabis cultivation
company and KALY’s NCM Biotech in the announcement scheduled for
Tuesday, July 14,
2020.
PURA’s cannabis
cultivation operation is thriving. The operation has recently
purchased and relocated to a new property from its former leased
property. Texas lawmakers have recently implemented hemp
friendly farming regulations and in so doing, universities within
the State of Texas have initiated hemp farming research
programs. PURA’s cannabis cultivation spinoff has initiated a
number of joint research applications with Texas
universities.
NCM Biotech is
focused on medical research and the development of treatments
derived from its patented cannabis extraction process. See a recent
research report on CBD extracts derived from NCM Biotech's patented
extraction process: Journal of Cannabis
Research.
For more
information on Puration, visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024